Apr 24, 2012: TiGenix Obtains Manufacturing License For European Production Facility
Mar 15, 2012: TiGenix Reports Sales Of €1.1m In 2011
Feb 16, 2012: TiGenix Announces Changes In Management Responsibilities
Nov 03, 2011: TiGenix Reports Q3 2011 Results
Aug 25, 2011: TiGenix Reports H1 2011 Results
Apr 29, 2011: TiGenix Announces Availability Of ChondroCelect In Belgium
Mar 17, 2011: TiGenix Reports Total Revenue Of €2.4m For 2010
List of Tables
TiGenix NV, Key Facts
TiGenix NV Key Pipeline Products by Equipment Type
TiGenix NV Key Pipeline Products by Therapy Area
TiGenix NV Key Pipeline Products by Development Stage
TiGenix NV Key Pipeline Products by Trial Phase
TiGenix NV, Key Facts
TiGenix NV, Major Products and Services
TiGenix NV Number of Pipeline Products by Equipment Type
TiGenix NV Pipeline Products by Equipment Type
TiGenix NV Number of Pipeline Products by Development Stage
TiGenix NV Pipeline Products by Development Stage
TiGenix NV Number of Pipeline Products by Therapy Area
TiGenix NV Pipeline Products by Therapy Area
TiGenix NV Number of Pipeline Products by Trial Phase
TiGenix NV Pipeline Products by Trial Phase
TiGenix NV Number of Pipeline Products By Milestone Summary
TiGenix NV Pipeline Products by Milestone Summary
ChondroCelect - Product Status
ChondroCelect - Product Description
ChondroCelect - Product Milestone
ChondroCelect - Prospective Multicenter Randomized Controlled Trial of ChondroCelect (in an Autologous Chondrocyte Transplantation Procedure) vs Microfracture in the Repair of Symptomatic Defects of the Knee
ChondroCelect - Patent Details1
ChondroCelect - Patent Details2
ChondroCelect - Patent Details3
ChondroCelect - Patent Details4
ChondroCelect - Patent Details5
ChondroCelect - Patent Details6
ChondroCelect - Patent Details7
ChondroCelect - Patent Details8
ChondroCelect 3D - Product Status
ChondroCelect 3D - Product Description
ChondroCelect 3D - Patent Details1
ChondroCelect 3D - Patent Details2
ChondroCelect 3D - Patent Details3
ChondroCelect 3D - Patent Details4
ChondroCelect 3D - Patent Details5
ChondroCelect 3D - Patent Details6
ChondroCelect 3D - Patent Details7
ChondroCelect 3D - Patent Details8
ChondroMimetic - Product Status
ChondroMimetic - Product Description
ChondroMimetic - Product Milestone
ChondroMimetic - Pilot Clinical Trial of Chondromimetic
ChondroMimetic - Patent Details1
ChondroMimetic - Patent Details2
ChondroMimetic - Patent Details3
ChondroMimetic - Patent Details4
ChondroMimetic - Patent Details5
ChondroMimetic - Patent Details6
ChondroMimetic - Patent Details7
ChondroMimetic - Patent Details8
ChondroMimetic - Patent Details9
ChondroMimetic - Patent Details10
ChondroMimetic - Patent Details11
ChondroMimetic - Bone Filler - Product Status
ChondroMimetic - Bone Filler - Product Description
TiGenix NV (TiGenix) is a publicly held biomedical cell therapy company. The company carries out the development of innovative local treatments for damaged and diseased tissues. It mainly focuses in the therapeutic area of Orthopedic, such as damaged cartilage and osteoarthritis joints. The company offers two marketed products, namely, ChondroCelect and ChondroMimetic. It also offers a strong product pipeline with clinical stage adult stem cell programs used for the treatment of inflammatory and autoimmune diseases. The company is developing a proprietary stem cell platform that can be used in cartilage, meniscus, bone, tendon and muscle tissue repair. Geographically, through its subsidiaries, the company has operations in Madrid, Spain; Cambridge, UK; and Sittard-Geleen, the Netherlands. TiGenix is headquartered in Leuven, Belgium.
The key business strategies of the company include enhanced focus on providing cell therapy treatments for damaged and diseased tissues. It also aims to maintain its existing partnerships and to enter new collaborative agreements to fuel its services. This is indicated by recent partnership and collaboration agreements signed with Finnish Red Cross Blood Service for ChondroCelect distribution in Finland and the acquisition of all outstanding shares in the Spanish cell therapy company, Cellerix. Currently, the company is carrying out a Phase IIa trial in rheumatoid arthritis. It also planning to start Phase III clinical trial in critical perianal fistulas in patients with Crohn’s disease and Phase I trial to identify the potential of intra-lymphatic administration of eASCs for the treatment of autoimmune disorders.
This report is a source for data, analysis and actionable intelligence on the TiGenix NV portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.
Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
Data on relevant clinical trials and product patent details, wherever applicable.
Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.
Reasons to Buy
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
Design and develop your product development, marketing and sales strategies.
Exploit M&A opportunities by identifying market players with the most innovative pipeline.
Develop market-entry and market expansion strategies.
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.